Foresite Capital Management VI LLC holds a concentrated book of 17 stocks worth $460.3M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Minerva Neurosciences Inc and trimmed Agios Pharmaceuticals Inc. Their largest long position is CG Oncology Inc at 33% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2013341/holdings"
Use Arkolith to show Foresite Capital Management VI LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
98% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | CG Oncology, Inc. COM | $150.3M | 2.22M | 32.7% | —Held | |
| 2 | Alumis Inc. COM | $93.6M | 4.25M | 20.3% | —Held | |
| 3 | Centessa Pharmaceuticals plc SPONSORED ADS | $54.2M | 1.36M | 11.8% | —Held | |
| 4 | Corvus Pharmaceuticals, Inc. COM | $26.8M | 1.83M | 5.8% | ▲+33% Added · +450K sh | |
| 5 | Denali Therapeutics Inc. COM | $23.2M | 1.21M | 5.0% | ▲+21% Added · +210K sh | |
| 6 | Agios Pharmaceuticals, Inc. COM | $17.8M | 525.0K | 3.9% | ▼−0.9% Reduced · −5K sh | |
| 7 | Verastem, Inc. COM | $16.7M | 3.15M | 3.6% | ▲+0.4% Added · +12K sh | |
| 8 | Kymera Therapeutics, Inc. COM | $12.2M | 146.3K | 2.6% | —Held | |
| 9 | Minerva Neurosciences, Inc. COM | $12.0M | 1.99M | 2.6% | ▲New New position | |
| 10 | Celldex Therapeutics, Inc. COM | $10.0M | 315.9K | 2.2% | ▲New New position | |
| 11 | AtaiBeckley Inc. COM | $9.7M | 2.75M | 2.1% | ▲New New position | |
| 12 | Hinge Health, Inc. CL A | $8.5M | 220.4K | 1.8% | ▲+63% Added · +85K sh | |
| 13 | Crinetics Pharmaceuticals, Inc. COM | $7.7M | 212.0K | 1.7% | ▲New New position | |
| 14 | OnKure Therapeutics, Inc. COM CL A | $6.0M | 1.45M | 1.3% | ▲New New position | |
| 15 | Jade Biosciences, Inc. COM | $4.5M | 320.0K | 1.0% | ▲New New position | |
| 16 | GH Research PLC ORD | $4.4M | 315.5K | 1.0% | ▲New New position | |
| 17 | Zura Bio Ltd CL A | $2.7M | 450.0K | 0.6% | ▲New New position |
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.